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ABSTRACT
Objective: Inflammatory processes may play an
important role in the development of acute coronary
syndromes in people with type 2 diabetes; thus,
strategies to control inflammation are of clinical
importance. We examined the cross-sectional
association between objectively assessed physical
activity and inflammatory markers in a sample of
people with type 2 diabetes.
Methods: Participants were 71 men and 41 women
(mean age=63.9±7 years), without a history of
cardiovascular disease, drawn from primary care
clinics. Physical activity was objectively measured
using waist-worn accelerometers (Actigraph GT3X)
during waking hours for seven consecutive days.
Results: We observed inverse associations between
moderate-to-vigorous physical activity (per 10 min) with
plasma interleukin-6 (B=−0.035, 95% CI −0.056 to
−0.015), interleukin-1ra (B=−0.033, 95% CI −0.051 to
−0.015), and monocyte chemotactic protein-1 (B=−0.011,
95% CI −0.021 to 0.000). These associations largely
persisted in multivariable adjusted models, although body
mass index considerably attenuated the effect estimate.
Conclusions: These data demonstrate an inverse
association between physical activity and inflammatory
markers in people with type 2 diabetes.
Inﬂammatory processes are believed to play
an important role in the prognosis of people
with type 2 diabetes, for example, being linked
with the risk of end-organ damage, such as dia-
betic retinopathy and cardiovascular disease
(CVD).1 2 Inﬂammation plays a pivotal role in
vulnerable plaque formation through lesion
necrosis and thinning of the ﬁbrous capsule
that can result in endothelial erosion or
plaque rupture, leading to acute coronary syn-
dromes.3 Thus, strategies to control low-grade
inﬂammation are of clinical importance.
Evidence from epidemiological studies of
healthy populations has demonstrated an
inverse association between physical activity
(PA) and markers of low-grade systemic
inﬂammation.4–6 Until now, most studies
have concentrated on C reactive protein
(CRP) due to the development of low-cost
reliable assays and commonplace use in
clinical practice. Other markers of inﬂamma-
tion, such as plasma interleukin-6 (IL-6) and
monocyte chemotactic protein-1 (MCP-1),
may be more relevant in the context of exer-
cise. The anti-inﬂammatory effects of exer-
cise could be explained by adiposity and
non-adiposity-related mechanisms. Exercise
could decrease the migration of macro-
phages to adipocytes via reduced proinﬂam-
matory cytokines such as IL-6 and MCP-1, or
decrease adipose tissue macrophages in the
production of IL-6 and MCP-1.7 8
Data are lacking in people with diabetes,
particularly using objective assessments of
PA. Objective assessment of PA is being
increasingly used to overcome biases of self-
report and provide data on the entire inten-
sity spectrum of PA across waking hours.9
The aim of this study was to examine the
association between objectively assessed PA,
adiposity, and novel inﬂammatory markers in
a sample of people with type 2 diabetes.
RESEARCH DESIGN AND METHODS
People with type 2 diabetes but without a
history of CVD were recruited from primary
care clinics in London and the University
College London hospital outpatient clinic. We
approached 36 clinics in the North London
area providing information sheets about the
study. General practitioners from 18 clinics
agreed to participate and subsequently
Key messages
▸ Physical activity is beneficial for controlling
diabetes, but the mechanisms remain poorly
understood.
▸ In this study, objectively assessed
moderate-to-vigorous intensity physical activity
was associated with novel inflammatory
markers.
▸ The inverse association between physical activity
and inflammatory markers was partly explained
through adiposity.
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recruited eligible patients. History of CVD was deﬁned by
physician diagnosis, which was veriﬁed by the general prac-
titioner when recruiting patients into the study.
Participants gave full informed written consent to partici-
pate in the study. Based on our previous research,5 6 we
anticipated low–moderate effect sizes (d = 0.25). Thus, a
sample size of N=100 would provide us with 80% power at
5% signiﬁcance level (two-tailed) to detect differences in
inﬂammatory markers relative to PA.
Participants wore an accelerometer (Actigraph GT3X,
Florida, USA) around the waist that records movement
on the vertical and horizontal axis, during waking hours
for seven consecutive days. The accelerometer provides
a measure of the frequency, intensity, and duration of
PA and allows classiﬁcation of activity levels as sedentary,
light, moderate, and vigorous. The raw accelerometry
data were processed in 60 s epochs using specialist soft-
ware (MAHUffe, Cambridge, UK) to produce a series of
standardized variables. All participants included in the
present analysis recorded a minimum of 10 h/day wear
time and provided data for 5 days after exclusion of the
ﬁrst and last days of wear. Non-wear time was deﬁned as
intervals of at least 60 consecutive minutes of 0 cpm. We
used cutoff points previously employed in samples of
older British adults10 to calculate daily times in each
activity intensity band: sedentary (<1.5 MET)
0–199 cpm, light (1.5–3 MET) 200–1998 cpm,
moderate-to-vigorous PA (MVPA; >3 MET) ≥1999 cpm.
All PA variables were converted to time (minutes) in spe-
ciﬁc PA intensities per valid day.
Following the week of Actigraph assessment, participants
reported to the laboratory for clinical assessments.
Measurements included height, weight, waist and hip cir-
cumference, blood pressure, and a non-fasting blood
sample taken from the antecubital fossa. BMI was calcu-
lated using weight (kg)/(height (m2)). Glycated hemoglo-
bin (HbA1c) concentration was assayed using boronate
afﬁnity chromatography, a combination of boronate afﬁn-
ity and liquid chromatography. The inﬂammatory marker
IL-6 was measured using a high-sensitivity ELISA (R&D
Systems, Oxford, UK). Other inﬂammatory markers
included IL-1ra and MCP-1, which were assayed using the
Magnetic Luminex Performance Assay Human CCL2/
MCP-1 multiplexed IL-1RA kit (R&D Systems) read on a
Luminex 200 (Bio-Rad). Coefﬁcients of variation for all
assays were less than 8%.
The primary outcome was IL-6 and analyses with other
more novel inﬂammatory markers (IL-1ra, MCP-1) were
treated as exploratory. Multiple linear regression was
employed to examine the cross-sectional association
between MVPA and log-transformed inﬂammatory
markers, making adjustments for Actigraph wear time,
age, sex, smoking, ethnicity, medications, HbA1c, and
ﬁnally BMI. We performed additional analyses to
examine associations between sedentary time and
inﬂammatory markers using the same statistical
approach. All analyses were conducted using SPSS V.21.
RESULTS
We recruited 140 participants, although after exclusion
of missing data (N=16 missing Actigraph data due to
technical failure; N=12 missing bloods) our analytic
sample comprised 112 men and women. Excluded parti-
cipants did not differ from the analytic sample on any
variables (eg, age=63.1±7 vs 63.9±7, p=0.63). The
descriptive characteristics of the sample are displayed in
table 1. Participants ranged from 50 to 75 years of age,
were largely Caucasian, and 48.2% were obese. The
majority (82.4%) of the sample was prescribed metfor-
min, and in 34.8% of them HbA1c was less than 6.5%
(48 mmol/mol); in 33.9% it was between 6.5% and
7.5% (48–58 mmol/mol), and in 31.3% it was over 7.5%
(58 mmol/mol). Participants wore the Actigraph on
average for 14.6 h/day, and 75.1%, 21.3%, and 3.6% of
wear time was spent in sedentary, light, and
moderate-to-vigorous activity categories, respectively.
MVPA was inversely associated with HbA1c (per
10 min increase, B=−0.13, 95% CI −0.25 to −0.06), and
with BMI (per 10 min increase, B=−0.80, 95% CI −1.23
to −0.37) after adjustment for covariables. We also
observed inverse associations between MVPA and all
inﬂammatory markers (table 2). The associations for
IL-6 and IL-1ra persisted in multivariable adjusted
models, although BMI considerably attenuated the
Table 1 Descriptive characteristics (n=112)
Variable*
Age 63.9±7.0
Sex (% men) 71 (63.4)
Smokers (%) 16 (14.4)
Ethnicity (%)
White 91 (81.3)
Asian 9 (8.0)
Afro-Caribbean 6 (5.4)
Other 6 (5.4)
Sedentary (min/day) 659.6±111.6
Light activity (min/day) 186.9±70.7
MVPA (min/day) 32.1±23.2
Actigraph wear time (min/day) 878.5±102.2
Body mass index (kg/m2) 30.9±5.6
HbA1c (% and mmol/mol) 7.2±1.3
(55±14.2)
Interleukin-6 (pg/mL) 2.1±1.3
Interleukin-1ra (pg/mL) 897.1±571.8
Monocyte chemotactic protein-1 (pg/mL) 119.3±32.7
Medications (%)
Oral antidiabetic 92 (82.4)
Injectable antidiabetic and insulin 11 (10.2)
Antihypertensive 80 (71.3)
Lipid lowering 87 (77.8)
Aspirin 41 (36.2)
*Data are presented as mean±SD unless otherwise stated.
Percentages are denoted in brackets.
HbA1c, glycated hemoglobin; MVPA, moderate-to-vigorous
physical activity.
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effects. Indeed, BMI was directly associated with IL-6
and IL-1ra, although not with MCP-1 (see online supple-
mentary table S1). In further sensitivity analyses, we
adjusted for individual types of medication with anti-
inﬂammatory properties (instead of total number),
including statins, β-blockers, aspirin, and metformin.
The results, however, remained unchanged in all
analyses.
We also examined associations between other domains
of activity, including sedentary and light activity, with
inﬂammatory markers. There was an association
between sedentary time and IL-6 (per 10 min increase,
B=0.007, 95% CI 0.00 to 0.013, p=0.053) after adjust-
ment for MVPA and all other covariables, although not
with any of the other inﬂammatory markers. There were
no associations between light-intensity activity and any
inﬂammatory markers (data not shown).
DISCUSSION
PA may be an important intervention to reduce inﬂam-
matory markers in clinical groups,11 although there are
currently little objective data in people with type 2 dia-
betes. We observed inverse associations between object-
ively assessed PA and several markers of inﬂammation.
In particular, a novel ﬁnding was the association with
MCP-1. MCP-1 secreted from white adipose tissue is
linked to tissue macrophage accumulation and insulin
resistance by inducing a chronic inﬂammatory state.12
Our data are consistent with several recent studies that
observed inverse, dose–response associations between
objectively assessed PA and inﬂammatory markers
among people with type 2 diabetes.13 14
The anti-inﬂammatory effects of exercise could be
explained by adiposity and non-adiposity related mechan-
isms. Exercise could decrease the migration of macro-
phages to adipocytes via reduced proinﬂammatory
cytokines such as IL-6 and MCP-1, or decrease adipose
tissue macrophages in the production of IL-6 and MCP-1.7
The expression of exercise-regulated muscle genes, such as
the transcriptional coactivator PGC1α, is thought to
promote anti-inﬂammatory effects through a transient
release of cytokines, and possibly explains some of the sys-
temic and beneﬁcial effects of exercise in non-muscle
tissue.8 Epidemiological and clinical trials also suggest that
adiposity and non-adiposity related mechanisms play a role
in the anti-inﬂammatory effect of exercise. Our data suggest
that BMI largely explained the associations between PA and
inﬂammatory markers. However, in previous epidemio-
logical studies of healthy participants, the association
between PA and markers of low-grade systemic inﬂamma-
tion is largely independent of adiposity.15 Data from clinical
trials are also inconsistent. In the 1-year follow-up of the
Finnish Diabetes Prevention study, increased
moderate-to-vigorous activity was associated with a reduction
in CRP and IL-6, independently of baseline BMI or changes
in BMI.16 In a 10-month randomized trial of older adults,
aerobic exercise training resulted in reduced CRP, and
these effects were partly mediated through a reduction in
central adiposity.17 Similarly, in a year-long trial of moderate
exercise training, CRP was lowered only in women who
were obese at study entry and only in participants who lost
greater than 2% body fat.18 These inconsistencies may, in
part, be also explained by the use of a variety of different
inﬂammatory markers, some of which may act via separate
mechanistic pathways. Nevertheless, the role of weight loss
remains unclear, as a recent intensive lifestyle intervention
focusing on weight loss did not reduce the rate of cardiovas-
cular events in overweight or obese adults with type 2 dia-
betes.19 This trial has, however, received criticism including
the use of more cardioprotective medicines in the control
group and lack of statistical power for a longer duration of
intensive lifestyle changes.
Inconsistencies in the literature might also be
explained by the use of crude assessments of adiposity,
as more precise measures of regional body fat tend to
reveal stronger mediating effects.17 In the present study,
BMI was strongly associated with IL-6 and IL-1ra, but not
with MCP-1. In previous studies, MCP-1 was associated
with visceral but not subcutaneous adipose tissue.20 Such
subtle effects are difﬁcult to detect using only BMI.
There has been substantial interest in the association
between sedentary activity and cardiometabolic
health.21 22 In our study, we have found inconsistent
associations between sedentary activity and inﬂammatory
markers, which are in contrast with a previous work in
healthy participants where associations between object-
ive sedentary time and CRP/IL-6 were observed after
controlling for MVPA.21 22 In our study, however, the
most consistent associations were observed for MVPA,
Table 2 Regression of MVPA on inflammatory markers
Model 1
B (95% CI)
Model 2
B (95% CI)
Model 3
B (95% CI)
Interleukin-6 −0.035 (−0.056 to −0.015) −0.035 (−0.056 to −0.014) −0.022 (−0.043 to −0.001)
Interleukin-1ra −0.033 (−0.051 to −0.015) −0.032 (−0.050 to −0.013) −0.014 (−0.030 to 0.003)
Monocyte chemotactic protein-1 −0.011 (−0.021 to 0.000) −0.009 (−0.020 to 0.002) −0.007 (−0.019 to 0.005)
Coefficients (unstandardized B) represent a 10 min increase in MVPA.
Model 1: adjusted for age, sex, Actigraph wear time.
Model 2: additionally adjusted for smoking, ethnicity, HbA1c, total number of medications.
Model 3: additionally adjusted for BMI.
BMI, body mass index; HbA1c, glycated hemoglobin; MVPA, moderate-to-vigorous physical activity.
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suggesting that participation in only moderate-to-intense
exercise decreases inﬂammatory markers in people with
type 2 diabetes. Further randomized trials are, however,
required to conﬁrm this. The count-based approach
used to assess PA intensity thresholds in this study has
some limitations, particularly in distinguishing between
sedentary and light activities. In sensitivity analyses,
however, using different cut points did not change the
results (data not shown).
The main limitation of this study is the cross-sectional
design, which precludes us from making any inferences
about direction or causality. However, a key strength was the
selection of community-dwelling people with diabetes from
primary care and outpatient clinics. None of the partici-
pants had a history of CVD and the analysis was adjusted for
markers of diabetes control (HbA1c) and medications as a
marker of disease burden. Thus, although reverse causation
is possible, in that individuals with more severe diabetes and
comorbidity were less able to undertake PA, it is unlikely to
explain our results. A further key strength was the use of
objective PA measures, which eliminated problems of recall
bias that plague more traditional self-report methods.
In summary, we have observed inverse associations
between objectively assessed PA and several inﬂammatory
markers. These data further support the beneﬁcial effects
of moderate-intensity PA in the management of diabetes.
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